BMC Cancels ₹1-Crore Blood Bank Analyser Over Cost Concerns

The Brihanmumbai Municipal Corporation (BMC) has cancelled the procurement of a ₹1-crore fully automated immunohematology analyser due to concerns over the high cost of proprietary reagents and consumables required to operate the machine.

The decision comes after months of opposition from health activists and experts, who argued that the machine would increase the recurring cost of blood banking procedures and make blood-related services more expensive for patients in civic hospitals.

Health activist Chetan Kothari had written to the BMC Commissioner and senior officials, seeking cancellation of the tender. He argued that the machine is primarily used in large private hospitals, where patients are charged extra for specialised blood compatibility tests, and is not suitable for civic hospitals serving economically weaker patients.

Kothari also pointed out that hospitals can charge ₹300 for antibody screening, ₹280 for cross-matching and ₹500 for phenotyping, warning that blood-related procedures in BMC hospitals could become costlier by ₹280 to ₹1,080 if the machine were introduced.

The procurement had drawn scrutiny at a time when blood banks in BMC hospitals were witnessing declining blood collection and recurring shortages. Experts had questioned the cost-effectiveness of introducing such high-end technology into the municipal healthcare system.

The BMC's decision to scrap the procurement ends a proposal that had sparked debate over its financial viability and impact on affordable blood banking services. The move is expected to save the civic body from incurring additional expenses on proprietary reagents and consumables.

The BMC's blood banks have been facing challenges in recent years, including declining blood collection and recurring shortages. The civic body has been exploring ways to improve blood banking services and make them more affordable for patients.

The cancellation of the procurement is a significant development, as it highlights the BMC's commitment to providing affordable healthcare services to its citizens. The civic body will now need to explore alternative solutions to improve blood banking services in its hospitals.

In recent years, the BMC has been working to improve its healthcare infrastructure and services. The cancellation of the procurement is a step in the right direction, as it prioritizes the needs of patients and the civic body's financial resources.

The decision is also a victory for health activists and experts, who had raised concerns about the potential impact of the machine on patients and the civic body's finances. It highlights the importance of transparency and accountability in the procurement process and the need for careful consideration of the financial and social implications of such decisions.

In conclusion, the BMC's decision to cancel the procurement of the ₹1-crore blood bank analyser is a significant development that highlights the civic body's commitment to providing affordable healthcare services to its citizens. The move is expected to save the civic body from incurring additional expenses and prioritize the needs of patients.